SUMMARY Five hundred and fifty six subjects, known to be homosexuals or intravenous drug abusers and seropositive for HIV antibody, were selected on the basis of their clinical statesymptom free, lymphadenopathy syndrome (LAS), AIDS related complex (ARC), and AIDS. The presence of antigenaemia and the humoral response to viral polypeptides was investigated. The prevalence of patients positive for p31 antibody was significantly increased in those with AIDS and detectable antigenaemia.
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Several observations in subjects infected with human immunodeficiency virus (HIV) have shown that the presence of antigenaemia and decreased antibody titres to major core protein (p24) are correlated with the onset and severity of clinical symptoms.
We studied the presence of antigenaemia and the humoral antibody response to gag (p55, p24, pl 7), pol (p66, p51 and p31), and env (gpl60, gpl2O, and gp4l) products in HIV seropositive subjects grouped on the basis of their clinical condition. Results obtained were analysed to verify whether antibodies to viral proteins, other than core proteins, presented clinically important variations when detectable titres of antigen were found.
Materials and methods
Serum samples obtained from 556 subjects, known to be homosexuals or intravenous drug abusers and selected on the basis of their antibody positivity to HIV, were tested for HIV antigen and antibody. The clinical states ofpatients was classified as: symtom free (n = 246), lymphoadenopathy syndrome (LAS) (n = 112), AIDS related complex (ARC) (n = 148) and AIDS (n = 50). All serum samples were stored at -200 C without preservatives until use.
All samples were analysed for the presence of HIV antibody by a commercial immunoenzymatic test (HIV Wellcome) performed and interpreted according to the manufacturer's instructions. The analysis of antibody pattern against individual HIV polypeptides was performed by immunoblotting using commercial strips (Du Pont, De Nemours, France) with HIV polypeptides blotted after polyacrylamide gel electroAccepted for publication 6 October 1988 phoresis (PAGE) separation. Each strip was incubated overnight with a 1/100 dilution of serum and the antigen antibody reaction was detected by a rabbit anti-human IgG biotin-avidin system. 4-chloro-1-naphthol was used as substrate. The comparison of blots was made in one session to verify any little variations in the intensity of bands.
Samples were assayed for the presence of HIV core antigen (p24) in a solid phase sandwich-type enzyme immunoassay with anti-HIV p24 fixed on to microtitre plate wells (Du Pont, De Nemours, France).
The presence of HIV p24 was shown by a monospecific biotinylated antibody. The amount of viral antigen was indirectly estimated measuring the amount of bound biotinylated antibody with a streptavidin horseradish-peroxidase conjugate and colour development after the addition of substrate.
All positive reactions obtained by HIV-1 p24 core antigen ELISA were always confirmed by a neutralisation test (HIV-1 p24 core antigen confirmatory test, Du Pont, De Nemours, France). Table 1 shows the percentage of reactivity of individual HIV polypeptides with antibody present in the various groups of human sera. A significant decrease in the percentage of antibody positive subjects, correlated with the increasing severity of clinical condition, was observed against p17, p51, and p55 and to a lesser extent against p3 1. Table 2 shows that 146 (26%) of the 556 subjects had detectable amounts of HIV antigen in serum, and 282
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Patterns ofantigenaemia and antibody response in HIV 283 Table 3 shows the prevalence of antibody against individual HIV polypeptides in relation to the presence or absence of p24 antigen. The decrease in the incidence of subjects' antibody reacting with p17, p24, and p55 in the various groups of subjects selected was more evident in patients with positive antigenaemia. By contrast, the incidence of subjects with serum antibody reacting to p31 was unexpectedly higher in the group with AIDS when antigenaemic subjects were examined alone. No significant differences were observed for other polypeptides. Discussion The antibody response to HIV individual envelope proteins occurred in all the sera tested. These data agree with those of other studies'2 which show that antibody response to gpl20 and gpl60 constantly occurs, irrespective of the presence and severity of clinical symptoms. As already described3 a decreased percentage of subjects with antibody to core proteins was observed 54  74  79  60  60  74  31  67  p24  77  90  100  83  75  91  69  83  p31  88  74  79  76  85  80  77  50  gp41  88  94  86  88  85  93  85  92  p51  81  74   50  69  60  65  38  58  p55  81  85  86  64  55  74  62  67   p66  96  94  79  88  80  89  77  92  gpl20  100  99  86  90  95  96  92  92  gpl60  100  100  100  100  100  98  100 
